explore -WSS

explore

author：focus 2025-09-01 05:55:28 - browse：7

Adobe

The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes.

Device makers have long complained that the unclear, rocky road to payment kills innovative companies. So they were thrilled when the Trump administration proposed a rule that would have guaranteed four years of Medicare coverage of approved devices deemed “breakthroughs” by the Food and Drug Administration. They hoped private payers would follow suit. But in 2021, under a new administration and a push for more device scrutiny, the Centers for Medicare and Medicaid pulled back on the idea, promising a replacement that would streamline coverage for innovative devices while ensuring safe, high-quality care.

The pathway put forth last week, called Transitional Coverage for Emerging Technologies (TCET), is only a notice, not yet a rule that would grant CMS new powers. The program applies solely to devices that have earned a place in the FDA’s breakthrough device program, which was established to identify devices that the agency believed could provide “more effective” treatment or diagnosis of serious conditions than the current standard of care. But because those devices can be brought to market with less certainty in their benefits and risks than other products, experts said, the idea of automatic reimbursement was dicey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： A new study asks: Are we harming blood donors by taking blood?

hotspot

WSS

Inside the fall of star MIT scientist David Sabatini

Patients' immediate access to test results puts radiologists in a bind

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Australia's humpback populations rebound raising hopes of marine scientists

Pfizer's Covid pill remains 89% effective in final analysis, company says

RaDonda Vaught case: a double standard for nurses, physicians

focus

explore

Wikipedia

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Why is France rioting? What to know about the fatal police shooting of Nahel M

Supreme Court strikes down use of affirmative action

PhRMA sues HHS over Medicare drug price negotiation

Wildfire smoke exposes gaps in outdoor worker protections

Community addresses injustice for Long Island mothers

Wildfire smoke exposes gaps in outdoor worker protections

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Bright Health sells Medicare Advantage business to Molina

Inside the fall of star MIT scientist David Sabatini

leisure time

Congenital heart disease patients face new threat of heart failure

RaDonda Vaught case: a double standard for nurses, physicians

Roche to buy Carmot Therapeutics, developer of obesity drugs

Congenital heart disease patients face new threat of heart failure

Van's Gluten Free Original Waffles recalled for possible wheat allergen

Spinal cord stimulation reduces pain in amputees, study finds

hotspot

knowledge

hotspot

focus